Skip to main content

Month: August 2025

Jeffs’ Brands Launches AI-Driven Crypto Treasury Program with $75 Million Committed for Optimized Yield from Five Leading Crypto Coins

The treasury will be managed by Quantum Crypto, an affiliate of Tectona Ltd, one of Israel’s largest public crypto companies which also holds a 41% stake in Horizon, a leading Israeli institutional crypto trading platform   Tel Aviv, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, recently announced its plan to implement a cutting-edge, artificial intelligence (“AI”)-driven crypto treasury management strategic plan (the “Treasury Program”). The Treasury Program will focus on optimizing yields from five leading cryptocurrencies, including Bitcoin and stable coins, leveraging advanced AI technology to enhance returns.  Subject to the successful setup of its crypto wallets, the Company intends...

Continue reading

Orbit International Corp. Reports 2025 Second Quarter Results

Second Quarter 2025 Net Loss of $1,290,000 ($0.39 loss per share) v. Net Loss of $201,000 ($0.06 loss per share) in Prior Year Comparable Period Second Quarter 2025 EBITDA, As Adjusted, was a loss of $1,049,000 ($0.32 loss per share) v. a loss of $405,000 ($0.12 loss per share) in Prior Year Comparable Period Six Months 2025 Net Loss of $3,442,000 ($1.03 loss per share) v. Net Loss of $952,000 ($0.28 loss per share) in Prior Year Comparable Period Six Months 2025 EBITDA, As Adjusted, was a loss of $2,998,000 ($0.90 loss per share) v. a loss of $965,000 ($0.29 loss per share) in Prior Year Comparable Period Backlog at June 30, 2025 was $12.5 million compared to $12.0 million at December 31, 2024 Company Commences Effort to Trim Costs at SPS Subsidiary to Better Align with Projected Revenue HAUPPAUGE, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE)...

Continue reading

Xcel Brands, Inc. Announces Second Quarter 2025 Financial Results

Social media following in brand portfolio increased from 5 million to 43 million in the 2nd quarter, which includes the previous announcements of new influencer brands during the current quarter. The current quarter 2025 revenues of $1.3 million, essentially flat compared with first quarter 2025, with minimal negative impacts to date from tariffs and current economic headwinds. Net loss on a GAAP basis was $4.0 million for the current quarter and $6.8 million on a year-to-date basis, inclusive of non-cash charges related to debt refinancing. Year-to-Date Adjusted EBITDA for 2025 was negative $1.0 million, compared with Adjusted EBITDA of negative $1.6 million for the first six months of 2024, representing a 38% improvement; the Company projects approaching break-even monthly Adjusted EBITDA by end of 2025.NEW YORK, Aug. 14, 2025 ...

Continue reading

ZenaTech Signs Offer to Acquire a Flight School Enabling Complex BVLOS Missions and Potential Drone as a Service (DaaS) US Government and Military Contracts

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces that it has signed an offer to acquire a Florida-based FAA (Federal Aviation Authority) certified flight school that trains professional pilots for FAA Part 61 certification to be qualified as an airplane pilot and also for complex BVLOS (Beyond Visual Line of Sight) drone pilot operations. Upon completion, the acquisition will enable the company to build an internal team of Part 61-certified pilots and be positioned as drone regulations evolve and opportunities grow in the DaaS, government, and defense markets,...

Continue reading

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025 A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosing The Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALS A Type B end-of-Phase 2 FDA meeting has been scheduled in the third quarter of 2025 to discuss the MS clinical development program Cash and cash equivalents of $7.3 million as of June 30, 2025, together with $1.9 million raised in equity and a $1.5 million increase in its convertible debt facility subsequent to June 30, 2025, provides cash runway...

Continue reading

America’s Car-Mart, Inc. Regains Compliance With Nasdaq Filing Requirements

ROGERS, Ark., Aug. 14, 2025 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“Car-Mart” or the “Company”), today announced that, the Company has regained compliance with the periodic filing requirement under The Nasdaq Stock Market LLC Listing Rule 5250(c)(1) (the “Rule”) based on the Company’s filing of its Annual Report on Form 10-K for the fiscal year ended April 30, 2025 with the U.S. Securities and Exchange Commission on August 8, 2025. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market on August 13, 2025, confirming the Company’s compliance with the Rule and stating that the matter is now closed. About America’s Car-Mart, Inc. The Company operates automotive dealerships in 12 states and is one of the largest publicly held automotive retailers in the United States focused...

Continue reading

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has advanced its proprietary sensing catheter through a final design review in preparation for human clinical trials. Previous versions had been used in animal models to demonstrate the ability to detect nerve signals. This marks a major step forward on the Company’s path toward initiating U.S. clinical studies. Autonomix’s...

Continue reading

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503. The reverse stock split is intended to enable Salarius to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market. At a special meeting of stockholders held on July 8, 2025, Salarius’ stockholders approved the proposal to authorize...

Continue reading

Amaze Reports Second Quarter 2025 Financial Results with 1,134% Year-Over-Year Revenue Growth

Accompanying Shareholder Letter Available at ir.amaze.co With Q2 Revenue Baseline, Company Expects Sequential Topline Growth for Remainder of 2025 NEWPORT BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today reported financial results for the second quarter ended June 30, 2025. Recent Operational HighlightsSurpassed 200 million lifetime storefront visits and 12 million active creators, underscoring the Amaze platform’s scale and influence in the rapidly expanding creator economy. Announced several marquee partnerships in recent weeks, including Alex Caruso, Jamvana, Loaded Dice, Nutrius, and Ghost Gaming, among others. Partnered with Picsart, allowing users to turn their digital art, edits, and designs into physical...

Continue reading

MDWerks Issues Mid-Year Shareholder Update

GREEN COVE SPRINGS, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — MDWerks, Inc. (“MDWerks” or the “Company”) (OTCQB: MDWK), a forward-thinking company leading the charge in the world of sustainable technology, today issued the following mid-year shareholder update from its Chief Executive Officer, Steven Laker. Dear Fellow Shareholders, Through mid-2025 we have made significant progress expanding our proprietary energy wave technology platform with innovative real-world applications that benefit our customers and position MDWerks for long-term sustainable growth and profitability. We currently are addressing large market opportunities in the alcoholic beverages and wood manufacturing industries, with innovations in other sectors on our radar. We are excited about MDWerks’ future and believe that we are on the cusp of substantially better...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.